Publication details

Kdy ukončit léčbu hepatitidy B?

Title in English When stop hepatitis B therapy?
Authors

HUSA Petr

Year of publication 2021
Type Article in Periodical
Magazine / Source Vnitřní lékařství
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.casopisvnitrnilekarstvi.cz/artkey/vnl-202101-0007_current-view-on-hepatitis-b-diagnosis-and-therapy.php?back=%2Fsearch.php%3Fquery%3D%2509Kdy%2Bukon%25E8it%2Bl%25E9%25E8bu%2Bhepatitidy%2BB%253F%26sfrom%3D0%26spage%3D30
Doi http://dx.doi.org/10.36290/vnl.2021.007
Keywords chronic hepatitis B; tenofovir; entecavir; stopping therapy
Description Hepatitis B virus (HBV) infection remains a global public health problem with changing epidemiology due to several factors predominantly vaccination policy and migration. Chronic hepatitis B is a dynamic process reflecting the interaction between HBV replication and the host immune response and not all patients with chronic HBV infection have chronic hepatitis B. Stopping of nucleotide or nucleoside analogues (NA) therapy is a serious resolution due the danger of reactivation of viral replication associated with increasing HBV DNA level, ALT activity and inflammatory activity in the liver histology. The safest stopping rule for NA therapy is HBsAg loss what is the sign of immune control of HBV infection.

You are running an old browser version. We recommend updating your browser to its latest version.

More info